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Bicuspid aortic valve is the commonest congenital cardiac abnormality in the general population. This paper article will discuss
our current knowledge of the anatomy, pathophysiology, genetics, and clinical aspects of bicuspid aortic valve disease.
1. Introduction
Bicuspid aortic valve (BAV) is the commonest congenital
cardiac abnormality with an estimated prevalence of 1-2%
[1]. It is almost 3 times more common in males than females
[2]. Adverse cardiovascular outcomes in patients with BAV
are more common than previously thought [3], therefore
given its high prevalence it presents potentially a large burden
on cardiovascular care.
This paper will discuss our current knowledge of the
anatomy, pathophysiology, genetics, and clinical aspects of
BAV disease using echocardiographic literature. Only BAV
will be discussed in this paper as well as sequelae directly
related to this.
1.1. Embryology. The definitive fetal cardiac structure is
developed by 8 weeks. The semilunar valves form the division
of the truncus arteriosus into two separate channels which
form the aortic and pulmonary trunks. The channels are
created by the fusion of two truncal ridges across the lumen.
Small swellings appear on the inferior margins of each of the
truncal ridges forming the basis of the adult valve leaflets. In
each channel a third swelling occurs opposite the first two
which will form the 3rd leaflet. In the normal aortic valve the
left and right leaflets of the adult valve are formed from the
respective swellings while the posterior leaflet is formed from
a swelling in the aortic trunk [4, 5].
The exact pathogenesis of the formation of bicuspid
aortic valves is not yet fully understood. It is thought there is
certainly a genetic component, especially given the associ-
ation of BAV with other congenital abnormalities such as
coarctation of the aorta. In summary however, the BAV is
formed by fusion of the aortic cusps during valvulogenesis.
The pulmonary valve can also be bicuspid, although this
is much rarer and is most commonly associated with con-
genital heart disease such as Tetralogy of Fallot. There have
been less than 10 cases reported in the literature of an isolated
bicuspid pulmonary valve [6].
1.2. Anatomy. The bicuspid valve is composed of two leaflets,
of which one is usually larger [7, 8] (Figure 1). The com-
monest configuration of the bicuspid valve has the two
commissures located in an anteroposterior direction giving
left and right cusps while slightly less common is having the
commissures located on the right and left sides of the annulus
leading to anterior and posterior cusps. Themost rare, occur-
ring in less than 1% of patients, is due to fusion of the left
and non-coronary cusps. A new classification has identified
these as type 1, 2, and 3 bicuspid aortic valves [9] (Figure 2).
A raphe is present on the right and anterior cusps respec-
tively, and this can make the valve appear tricuspid on echo-
cardiography. The site of cusp fusion can have eﬀects on the
prognosis of BAV [10], with the suggestion that type 1 BAVs
are more likely to stenose as adults while type 2 valves will
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Figure 1: The basic anatomy of the bicuspid aortic valve.
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Figure 2: The classification and incidence of bicuspid aortic valves
according to site of cusp fusion.
have complications at a younger age. The fused valve leaflet
in BAV is actually smaller in area than the total area of two
separate leaflets would be if the valve were tricuspid.
As well as valvular lesions there can be several associated
nonvalvular lesions. The coronary anatomy can be abnormal.
Most patients with BAV disease have a left dominant coro-
nary circulation [8]. This left coronary can arise from the
pulmonary artery. The left main can also be up to 50%
shorter than in normal in up to 90% of cases [11]. This is
an important consideration for any aortic valve surgery.
The commonest abnormality associated with BAV is
dilatation of the thoracic aorta, also known as aortopathy.
This is thought not only to be due to the altered flow in
the aorta, but also due to cellular structural abnormalities
including decreased fibrillin, causing smooth muscle cell
detachment, and cell death [12].
The other major abnormality found in conjunction with
BAV disease is coarctation of the aorta. This occurs in at least
20% of cases and perhaps up to 85% [13, 14]. The presence
Bicuspid aortic valve-anterior-posterior commissure
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Figure 3: The bicuspid valve in the parasternal short axis view.
of coarctation and a poor result from repair can lead to more
rapid failure of the valve or aortic dissection.
1.3. Genetics. It is now generally accepted that there is a
heritable component to BAV disease. Reports have estimated
that there is around a 10% chance of a first degree relative
having a bicuspid aortic valve in patients with the disease
[15, 16]. A further study indicated a prevalence of almost a
quarter in families with more than one member with BAV
[17].
The connection of BAV disease and other cardiac abnor-
malities again suggests that there may be a developmental
link. BAV has been found in just over a quarter of patients in
a case series of 52 patients with interrupted aortic arch [18].
Mutations in a gene called NOTCH1, a transmembrane
receptor that has a role in determining cell outcome in
organogenesis, were noted in two families with BAV [19].
This seems to be the strongest genetic link discovered yet with
further discoveries of missense NOTCH1 mutations causing
impaired Notch signalling [20, 21]. Several other genetic loci
have been postulated including chromosomes 18q, 5q, and
13q, though no specific genes have been found.
Recent guidance from the American College of Cardi-
ology/American Heart Association takes into account the
genetic component and recommends that all patients with a
1st degree relative with BAV should be evaluated for BAV and
aortopathy [22]. No studies have been done as yet however to
prove an economic benefit to screening; however recent work
has been done to suggest that there is a suﬃcient pick-up rate
of disease if first degree relatives are screened [23].
2. Diagnosis
Clinical findings are usually limited to auscultation with
most patients having an ejection systolic murmur heard
loudest at the apex [24]. There may also be signs of aortic
stenosis and coarctation of the aorta if associated. The elec-
trocardiogram is usually normal; however there may be signs
of left ventricular hypertrophy.
The mainstay of diagnosis is echocardiography (trans-
thoracic or transoesophageal) which can provide a definitive
diagnosis in the majority of patients (Figure 3). Figures of
92% sensitivity and 96% specificity have been reported when
images are adequate [25, 26]. Due to the natural history
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of BAV to lead to heavily calcified stenotic valves, the utility
of echocardiography can be limited [27].
The parasternal short axis view allows for direct visual-
ization of the valve cusps. In this view the normal triangular
opening shape is lost, becoming more “fish mouth-”like in
appearance, more akin to the mitral valve. This is especially
pronounced in systole, as in diastole the raphe can appear
similar to a commissure of the third cusp.
A further useful aspect of echocardiography is its ability
to identify other cardiac abnormalities including vegetations,
systolic dysfunction, and visualisation of part of the aortic
root (generally the first 3-4 cm). It is not able however to fully
quantify the extent of any aortopathy (whether proximal or
distal).
Because of these 2 main limitations, cardiac MRI and
CT have been used to augment the diagnostic process. MRI
especially will enable views of the valve to be obtained with-
out interference from calcification. It also allows for excellent
assessment of the aorta. A recent study of 123 patients with
confirmed BAV found that 10% of the patients were misiden-
tified as having a tricuspid valve using transthoracic echo
and 28% had a nondiagnostic study, in comparison to 4%
being misidentified as having a tricuspid valve by magnetic
resonance imaging and 2% having a non-diagnostic study
[28]. There is certainly a role for cardiovascular MRI in the
assessment of BAV. Additionally, both imaging modalities
could be employed to assess the presence and extent of
aortopathy making them as excellent surveillance tools.
3. Clinical Progression
The natural history of BAV has been evaluated several cohort
studies. It is known to be variable and of course somewhat
dependent on associated abnormalities. It can range from
severe aortic stenosis in childhood to asymptomatic disease
until old age. There have indeed been incidental findings
of a minimally calcified BAV in patients in their 70s [29].
More commonly however (in around 75% of patients) there
is progressive fibrocalcific stenosis of the valve eventually
requiring surgery. This usually leads to presentation in
middle age—only around 2% of children have clinically
significant BAV disease [30].
There have been a couple of studies looking at long-term
followup of patients with unoperated BAV. A cohort of 212
asymptomatic patients [31] with BAV (age 32 ± 20 years)
were found to have the same 20-year survival rate as the nor-
mal population (around 90%) but an increased frequency of
cardiac events including aortic valve surgery, ascending aorta
surgery and any other cardiovascular surgery. Predictive fac-
tors for cardiovascular events were found to be age ≥50 years
and valve degeneration at diagnosis while baseline ascending
aorta ≥40mm independently predicted surgery for aorta
dilatation.
Another cohort study [3] looked at outcomes in patients
with symptomatic and asymptomatic bicuspid valve disease
(mean age 35 year, median 31, range 16–78). 642 patients
were followed up for a mean of 9 years, again with a 10-year
survival rate similar to the normal population (96%). One
or more primary cardiac events occurred in 25% including
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Figure 4: Outcomes in BAV patients (from Tzemos et al. [3]).
cardiac death in 3, intervention on aortic valve or ascending
aorta in 22%, aortic dissection or aneurysm in 2%, and
congestive heart failure requiring hospital admission in 2%.
Independent predictors of primary cardiac events were age
older than 30 years, moderate or severe aortic stenosis, and
moderate or severe aortic regurgitation (Figure 4).
A more recent study has looked at the incidence of aortic
complications in 416 BAV patients (mean and median age 35
years, range <1–89) [32]. Incidence of aortic dissection was
found to be 1.5% in all patients regardless of the progression
of BAV; however this increased markedly in patients aged 50
or older at baseline to 17.4% and evenmore in those found to
have aneurysm formation at baseline to (44.9%). 25-year rate
for aortic surgery was 25% and there was a significant burden
of progression of disease to cause aortic dissection with 49
of the 384 patients without baseline aneurysms developing
them during followup, giving an age-adjusted relative risk of
86.2 and an incidence of 84.9 cases per 10000 patient-years.
Themain complications identified in these cohort studies
in patients with BAV are aortic stenosis, aortic incompetence,
aortopathy/dissection, endocarditis, and sudden death.
3.1. Aortic Stenosis. The symptoms of the BAV tend to
worsen with increasing stenosis severity, and measurements
of the valve orifice. The main symptoms are (exertional) dys-
pnea, syncope, and chest pain. These patients should be eval-
uated andmanaged similarly to patients with tricuspid aortic
valve stenosis, but of course the patients will generally
present much earlier as described previously.
The foetus can generally survive with severe aortic
stenosis due to blood flow through the right side of the heart;
however in infancy there is usually a sudden decline in car-
diovascular status. One study indicated that children with
a valve gradient greater or equal to 50mmHg had a risk of
adverse cardiovascular events of 1.2% per year [33].
In adults with BAV, stenosis occurs by similar methods
to the process in patients with tricuspid aortic valves. It is
felt to be due to leaflet calcification. It is however more likely
to be present in patients by 40 years old. There has been a
suggestion that leaflet orientation may be a predictive factor
in the rate of valve stenosis [34, 35]; however this was not
replicated in the larger studies mentioned earlier [2, 31].
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3.2. Aortic Incompetence. This is relatively common in BAV
and is often independent of aortic stenosis [36, 37]. One
cohort of 118 BAV patients found that of 70 patients without
aortic stenosis, 28 (40%) had moderate to severe aortic
regurgitation. The mechanisms of aortic incompetence in
children are usually due to prolapsing cusps, postvalve
surgery or endocarditis, while as the patients age dilatation of
the ascending aorta can lead to a functionally regurgitant
valve. Tzemos et al. [3] however suggested that rates of inter-
vention in BAV patients with solitary aortic incompetence
tended to be low. Another important cause of aortic incom-
petence is myxoid degeneration of the valve. This is where
the connective tissue of the valve is replaced by acid mu-
copolysaccharides disrupting the structural integrity of the
valve. One case series included 27 patients with BAVwho had
pure aortic incompetence—16 of these had severe myxoid
degeneration and required earlier intervention than the other
11 (average 40 years versus 52) [38].
3.3. Aortopathy/Aortic Dissection. BAV is often associated
with dilatation of the aortic root and the ascending aorta
[39]. This is otherwise known as aortopathy. This can lead to
aneurysm and dissection. The dilatation has been reported
during childhood, and it has also been suggested that
increased aortic size at baseline is predictive for earlier dilata-
tion and worse outcomes [40, 41]. Aortic size is larger gen-
erally in patients with BAV compared to those with normal
valves [42]. The most likely risk factor for progression is felt
to be age. Aortic root size itself is related to valve morphology
and the presence of significant disease [43, 44]; however, a
recent study did suggest that while most patients with BAV
and ascending aortic aneurysm had severe valve dysfunction,
there was a small proportion of patients (5%) who did have
aneurysm formation without any aortic valve dysfunction
[45].
Many theories have been postulated for the mechanism
of BAV aortopathy. For a long time there has been felt to be a
genetic component; however there is increasing evidence for
a haemodynamic mechanism. It is felt that it is due to defects
in the aortic media, such as elastin fragmentation, loss of
smooth muscle cells, and an increase in collagen [46–49].
Systemic features have also been noted in BAV patients which
may predispose to aneurysm formation including systemic
endothelial dysfunction and higher plasma levels of matrix
metalloproteinases [50]. Also noted has been an increased
amount of wall stress in the ascending aorta [51].
Aortic dissection is a devastating concern in these
patients; however the incidence of this has been variable in
the studies, from no events [31] and 0.1% [3] in the larger
studies, up to 4% in pooled earlier studies [52]. Risk stratifi-
cation for bicuspid aortic valve and development of aortopa-
thy still has a long way to go as there has so far appeared to be
little correlation between echocardiographic and histologic
findings and development of aortic disease [53, 54]. Recent
advances in echocardiography may help to identify at-risk
patients in future [55].
There is still a lot of evidence pointing towards a genetic
origin. 4 “important lines of evidence” have been identified
for the genetic theory [56]: (1) greater aortic size in patients
with BAVs and aortic stenosis compared with those with
tricuspid valves and aortic stenosis who are matched for
hemodynamic severity [57]; (2) enlarged aortas are found
in patients (including children) with BAVs but without any
aortic stenosis or aortic regurgitation, compared with age-
matched normal controls [58, 59]; (3) studies have demon-
strated progressive enlargement of the aorta after aortic
valve replacement (AVR) in patients with BAVs [60, 61], (4)
studies have demonstrated degeneration of the extracellular
matrix of the aorta in patients with BAVs, including elastic
fiber fragmentation, increased metalloproteinase expression,
decreased expression of tissue inhibitors of metallopro-
teinases, and smooth muscle cell apoptosis as mentioned
previously [50].
3.4. Endocarditis. Endocarditis is more common in BAV. The
estimated incidence is 0.16% per year in unoperated children
and adolescents [62]. In adults the two large case series by
Tzemos andMichelena give an incidence of 0.3% and 2% per
year, respectively.
Outcomes in BAV patients with infective endocarditis
tend to be worse than in those with normal valves. A recent
observational study [63] of 310 patients with infective endo-
carditis found that the 50 patients with BAV were younger at
presentation and had a higher incidence of aortic perivalvu-
lar abscess. Early surgery was also performed in most of the
BAV patients (72%) with similar perioperative mortality to
those with tricuspid aortic valves. In-hospital mortality and
5-year survival were also comparable to patients with normal
valves.
4. Management
The only treatments to oﬀer any sort of curative option are
surgical. Medical therapies are to try and alleviate symptoms
and slow progression.
4.1. Medical. It is generally felt that blood pressure should
be aggressively controlled to try and slow the progression
of aortopathy. The joint ACC/AHA guidelines suggested use
of beta-blockers as first-line therapy in these patients [63].
Extrapolating from patients with aortopathy in Marfan
syndrome there is also a suggestion that ACE inhibitors may
have a role to play; however the evidence in BAV is still
lacking [64].
Of course, concomitant conditions and risk factors
should be treated as in the normal population.
4.2. Surgical. Indications for valve surgery in patients with
BAV are similar to those with tricuspid aortic valves. In chil-
dren it is usually not practical to do aortic valve replacement
as they outgrow the prosthetic valve. Due to the lack of valve
calcification in children balloon valvuloplasty is possible
and is the management strategy of choice [30]. Studies have
shown good followup in both the immediate and medi-
umterms, with 50% of patients in one series (the majority
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of whom had BAV) requiring no intervention at 38 months
[65].
The 2006 AHA/ACC guidelines also suggest concomitant
replacement of the ascending aorta if it is greater than 45mm
in diameter. This has been supported by evidence looking at
outcomes in over 200 patients with varying aortic diameters
[66]. Estimated 15-year freedom from complications was
86% in patients with an aortic diameter less than 40mm,
dropping down to 81% in those with diameter 40–44 and
43% in patients with a diameter 45mm or greater.
New techniques of repair such as transcatheter aortic
valve implantation have also been reported in BAV [67].
5. Conclusion
Bicuspid aortic valve disease is the commonest congenital
cardiac abnormality, and because of this it presents a signif-
icant burden on cardiac services. Recent cohort studies have
given us knowledge of the outcomes of the disease and when
to operate; however there is still a need for further evidence
for screening and for medical therapies to be evaluated. Also,
the role of cardiovascular magnetic resonance as primary
imaging tool will continue to enlarge. As our understanding
of the pathogenesis of valve degeneration and aortopathy
improves this will allow us to identify new targets for
treatment.
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